🇺🇸 FDA

Company profile · Sponsor

Pierre

Pierre Fabre Medicament

E0A0F6B · EMA pharma LAVAUR, FR
Pipeline
7
Drugs
0
Patents
0

Quick answer

Pierre (E0A0F6B) is a pharma company. headquartered in LAVAUR, FR. listed on EMA. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E0A0F6B
Exchange EMA
Company type pharma
Headquarters LAVAUR, FR

Pipeline (7)

Search pipeline →

  1. EBVALLO

    Pierre

    Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease

    phase 3 small molecule active

    1 trial

  2. NICOPASS 1,5 mg SANS SUCRE MENTHE FRAICHEUR, pastille édulcorée à l'aspartam et à l’acésulfame potassique, V0018 Placebo

    Pierre

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  3. A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations

    Pierre

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 other active

    1 trial

  4. EBVALLO

    Pierre

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  5. ER004

    Pierre

    X-linked hypohidrotic ectodermal dysplasia (XLHED)

    phase 2 small molecule active

    1 trial

  6. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  7. A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

    Pierre

    Participants with BRAF and/or NRAS mutation positive tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is Pierre?

Pierre (E0A0F6B) is a pharma company. headquartered in LAVAUR, FR. listed on EMA. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Pierre sponsor?

We track 7 ClinicalTrials.gov-linked programs for Pierre, including EBVALLO and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Pierre company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.